JANUX THERAPEUTICS INC (JANX) Stock Analyst Ratings
USA - NASDAQ:JANX - US47103J1051 - Common Stock
27.81 USD
-1.95 (-6.55%)
27.8 USD
-0.01 (-0.04%)
ChartMill assigns a Buy % Consensus number of 87% to JANX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 79.97. This target is 187.55% above the current price.
JANX was analyzed by 23 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about JANX.
In the previous month the buy percentage consensus was at a similar level.
JANX was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-17 | Barclays | Initiate | Overweight |
| 2025-09-10 | Stifel | Reiterate | Buy |
| 2025-09-10 | Truist Securities | Initiate | Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-07-11 | Raymond James | Initiate | Outperform |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-28 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-12-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-04 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-12-03 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-12-03 | Stifel | Maintains | Buy -> Buy |
| 2024-12-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-22 | Leerink Partners | Initiate | Outperform |
| 2024-11-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | UBS | Initiate | Buy |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Stifel | Initiate | Buy |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-08-08 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-30 | ScotiaBank | Initiate | Sector Perform |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-04-16 | JonesTrading | Initiate | Buy |
| 2024-03-21 | BTIG | Initiate | Buy |
| 2024-03-20 | Cantor Fitzgerald | Initiate | Overweight |
JANUX THERAPEUTICS INC / JANX FAQ
Can you provide the average price target for JANUX THERAPEUTICS INC stock?
23 analysts have analysed JANX and the average price target is 79.97 USD. This implies a price increase of 187.55% is expected in the next year compared to the current price of 27.81.
What is the consensus rating for JANUX THERAPEUTICS INC (JANX) stock?
The consensus rating for JANUX THERAPEUTICS INC (JANX) is 86.9565 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed JANUX THERAPEUTICS INC (JANX)?
The number of analysts covering JANUX THERAPEUTICS INC (JANX) is 23.